Browsing tag:

Restless Legs Syndrome

Known as Restless Legs Syndrome, or RLS, this disruptive condition occurs in roughly 7% of the population worldwide. While patients older than age 65 are most commonly diagnosed, there are children who experience RLS as well. With approximately 10% of children experiencing a sleep disorder globally, the diagnosis of RLS in the adolescent population is[…]

Read More

Gabapentin Enacarbil, CAS number 478296-72-9, is also known as Horizant, which is marketed by GlaxoSmithKline. As a medication approved by the FDA to treat Moderate-to-Severe Primary Restless Legs Syndrome {RLS}, this drug is a welcome relief for patients who suffer from this frustrating neurological condition. RLS is more likely to occur in women, and includes[…]

Read More

Levodopa is typically prescribed alongside carbidopa to treat Parkinson’s disease. Brand names Sinemet and Sinemet CR are comprised of levodopa and carbidopa, and systemic levodopa can be found under the names Dopar and Larodopa. Classified as a dopaminergic antiparkinsonism agent, levodopa is also used to treat Periodic Limb Movement Disorder and Restless Legs Syndrome when[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service